Why did NOVARTIND.BO stock fall sharply pre-market on 25 Feb 2026?

The drop was driven by technical profit-taking after overbought signals (RSI **78.05**) and high MFI. Low headline volume and a gap down from **INR 1004.80** to **INR 830.45** amplified selling; no confirmed company-specific negative news was released at the time.

What are the immediate support and resistance levels for NOVARTIND.BO stock?

Immediate support is near **INR 825.00** and the 50-day average **INR 799.27**. Resistance sits at **INR 858.90** and the 200-day average **INR 895.45**. Watch relative volume to confirm breakouts or breakdowns.

How does Meyka AI view Novartis India’s near-term outlook?

Meyka AI rates NOVARTIND.BO **74.20 (B+, BUY)** and projects a yearly target of **INR 929.31**, implying **11.91%** upside from current levels. The model also flags a 3-month level at **INR 702.62**, so risk management is essential.

Which financial metrics should investors check for NOVARTIND.BO stock?

Key metrics include trailing EPS **INR 39.36**, PE **24.03**, PB **3.20**, dividend per share **INR 25.00**, and current ratio measures. Compare these to healthcare peers before making allocation decisions.

IN Stocks

NOVARTIND.BO Novartis India BSE -17.35% INR 830.45 Pre-Mkt Feb 2026: outlook

ByHuzaifa Zahoor February 25, 2026

The NOVARTIND.BO stock opened the pre-market session on 25 Feb 2026 under heavy selling, trading at INR 830.45, down 17.35% from a previous close of INR 1004.80. The move shows sharp profit-taking after a YTD gain of 21.44% and follows clear technical overbought signals. We break down price drivers, valuation and a short-term outlook for Novartis India Limited (BSE), and flag key support and resistance levels to watch before the market opens.